Immuron (IMRN) Non Operating Income (2018 - 2023)
Immuron's quarterly Non Operating Income came in at $149501.0 in Q4 2023, up 201.59% year-on-year from $49571.0 in Q4 2022, and up 201.59% quarter-over-quarter from $49571.0 in Q4 2022.
Immuron has reported Non Operating Income for 6 years, with the latest figure at $149501.0 in Q4 2023.
- For the quarter ending Q4 2023, Non Operating Income rose 201.59% year-over-year to $149501.0; the trailing twelve-month figure through Dec 2023 stood at $199121.8 (up 301.46% YoY), and the FY2025 full-year result was $83324.2, down 60.32% from the prior year.
- Non Operating Income for Q4 2023 stood at $149501.0, up from $49571.0 in the prior quarter.
- The five-year high for Non Operating Income was $149501.0 in Q4 2023, with the low at -$20.87 in Q4 2019.
- Average Non Operating Income over 5 years is $39820.2, with a median of $65.87 recorded in 2021.
- Year-over-year, Non Operating Income sank 153.51% in 2019 and surged 75154.62% in 2022.
- Tracing IMRN's Non Operating Income over 5 years: stood at -$20.87 in 2019, then rose by 22.81% to -$16.11 in 2020, then surged by 508.88% to $65.87 in 2021, then surged by 75154.62% to $49571.0 in 2022, then surged by 201.59% to $149501.0 in 2023.
- The last three Non Operating Income figures came in at $149501.0 (Q4 2023), $49571.0 (Q4 2022), and $65.87 (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 149,501.00 |
| Dec 31, 2022 | 49,571.00 |
| Dec 31, 2021 | 65.87 |
| Dec 31, 2020 | -16.11 |
| Dec 31, 2019 | -20.87 |
| Dec 31, 2018 | 39.00 |